LHRH-Analoga zur Androgendeprivation beim Prostatakarzinom. Eine Evidenzlevelanalyse

Zusammenfassung

In diesem Übersichtsartikel sollen die Indikationen und der Einsatz der LHRH-Analoga in der heutigen Zeit dargestellt und erläutert werden. Hierzu erfolgte eine Literatursuche in Pubmed und der Cochrane-Datenbank. Ebenso wurden Leitlinien der EAU wie auch der AUA, sowie aktuelle Kongressbeiträge bis 2008 berücksichtigt. Seit 1991 erstmals in einer prospektiven Studie die Äquieffektivität der LHRH-Analogatherapie gegenüber der Orchiektomie beim metastasierten Prostatakarzinom bewiesen werden konnte, wurde der Einsatz der LHRH-Analoga zunehmend ausgebaut. Unter dieser Therapie erscheint eine Kontrolle der Testosteronspiegel nur sinnvoll, falls unter der LHRH-Analogatherapie ein PSA-Anstieg zu verzeichnen ist. Nach Absetzen der LHRH-Analogatherapie dauert es umso länger bis sich die Testosteronwerte erholen, je länger mit LHRH-Analoga therapiert worden ist. Hierbei ist zu beachten, das nach einer Therapiezeit von über 3 Jahren auf die mögliche Entwicklung einer Osteoporose oder eines Diabetes hingewiesen werden muss. Bei der neoadjuvanten und adjuvanten Androgendeprivation zeigt sich folgendes: vor einer radikalen Prostatektomie senkt eine Hormontherapie die Rate positiver Schnittränder und Lymphknotenmetastasen, aber eben nicht das tumorfreie Überleben. Vor einer Radiotherapie hingegen verbessert eine maximale Androgenblockade das PSA-freie Überleben. Die adjuvante Hormontherapie nach radikaler Prostatektomie verlängert das krankheitsfreie Überleben. Die ­adjuvante Hormontherapie nach Radiatio ver­längert das krankheitsfreie Überleben ebenso. Eine erhöhte kardiovaskuläre Toxizität wurde nicht bestätigt. Eine intermittierende Androgendeprivation erscheint genauso wirksam wie eine kontinuierliche Behandlung unter Reduktion der Nebenwirkungen. Eine Salvage-Hormontherapie ist bei einer kurzen PSA-Verdopplungszeit oder PSA-Anstiegsgeschwindigkeit von > 2 ng / ml / Jahr indiziert. Der Wert eines frühen Beginns (PSA ≤ 10 ng / ml, PSA Verdopplungszeit ≤ 12 Monate) kann das metastasenfreie Überleben hierbei verlängern.

Abstract

In this review the current indications and the options for LHRH analogues are elucidated. For this purpose, a literature search in PubMed and the Cochrane-Database was performed. In addition, the EAU and AUA guidelines as well as actual meeting abstracts up to 2008 were taken into account. Since the first prospective study in 1991 showed the same effectivity for LHRH analogues and orchiectomy in metastasised prostate cancer patients, the use of LHRH analogues increased thereafter. Testosterone levels do not need to be checked regularly, but rather only when PSA rises again under treatment. After cessation of LHRH analogue treatment the time to testosterone level recovery is longer when the treatment time was longer. One must especially recognise the risks of diabetes and osteoporosis after more than 3 years of LHRH analogue treatment. In the case of neoadjuvant and adjuvant LHRH analogue treatment, several points have to be taken into consideration: LHRH analogues before radical prostatectomy lead to a lower positive margin rate and lower rate of lymph node metastasis, but tumour-specific survival is not improved. In contrast, neoadjuvant LHRH analogue treatment before radiation therapy leads to better tumour-specific and overall survival. An increased cardiovascular toxicity was not observed. Intermittent androgen ablation has been proved to be equivalent with a reduction of side effects. Hormonal salvage therapy should be initiated when the PSA doubling time is short or the PSA velocitiy is > 2 ng / mL / year. The benefit of early initiation (PSA < 10 ng / mL, PSA doubling time < 12 months) is that it can prolong the metastasis-free survival time.

Prostatakarzinom - LHRH-Analoga - PSA - Hormontherapie - Metastasen

prostate cancer - LHRH analogues - PSA - hormonal therapy - metastasis

Literatur

• 1 Labrie F, Belanger A, Luu-The V et al. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.  Endocr Rev. 2005;  26 361-379
• 2 The Leuprolide Study Group . Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group.  N Engl J Med. 1984;  311 1281-1286
• 3 Kaisary A V, Tyrrell C J, Peeling W B et al. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma.  Br J Urol. 1991;  67 502-508
• 4 Rajfer J, Swerdloff R S, Heber D M. Testicular histology following chronic gonadotropin-releasing hormone agonist treatment.  Fertil Steril. 1984;  42 765-771
• 5 Johansen T E, Ogreid P, Kjellevold K et al. Testicular histology after treatment with LH-RH analogue for carcinoma of the prostate.  Br J Urol. 1990;  65 376-378
• 6 Bubley G J. Is the flare phenomenon clinically significant?.  Urology. 2001;  58 5-9
• 7 Debruyne F M, Dijkman G A, Lee D C et al. A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: results of studies in prostate cancer.  J Urol. 1996;  155 1352-1354
• 8 Oefelein M G, Resnick M I. Effective testosterone suppression for patients with prostate cancer: is there a best castration?.  Urology. 2003;  62 207-213
• 9 Pathak A S, Pacificar J S, Shapiro C E et al. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.  J Urol. 2007;  177 2132-2135
• 10 Fujii Y, Yonese J, Kawakami S et al. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.  BJU Int. 2008;  101 1096-1100
• 11 Oefelein M G, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.  J Urol. 2000;  164 726-729
• 12 Morote J, Orsola A, Planas J et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.  J Urol. 2007;  178 1290-1295
• 13 Yri O E, Bjoro T, Fossa S D. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer.  Eur Urol. 2006;  49 54-58
• 14 Smith M R. Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer.  Clin Cancer Res. 2007;  13 241-245
• 15 Pickles T, Agranovich A, Berthelet E et al. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma.  Cancer. 2002;  94 362-367
• 16 Pedraza R, Kwart A M. Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression?.  Urology. 2003;  61 770-773
• 17 Vogelzang N J, Chodak G W, Soloway M S et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group.  Urology. 1995;  46 220-226
• 18 Seidenfeld J, Samson D J, Hasselblad V et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.  Ann Intern Med. 2000;  132 566-577
• 19 Keating N L, O’Malley A J, Smith M R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.  J Clin Oncol. 2006;  24 4448-4456
• 20 Bolla M, van Tienhoven G, de Reijke T M EORTC Radiation Oncology and Genito-Urinary Tract Cancer Groups et al.. Six months versus three years concomitant and adjuvant hormonal treatment combined with external beam radiation for locally advanced prostate cancer. 2007; suppl
• 21 Efstathiou J A, Bae K, Shipley W U et al. Cardiovascular Mortality and Duration of Androgen Deprivation for Locally Advanced Prostate Cancer: Analysis of RTOG 92-02.  Eur Urol. 2008;  54 816-824
• 22 Graff J N, Mori M, Li H et al. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study.  J Urol. 2007;  177 1307-1312
• 23 Shahinian V B, Kuo Y F, Freeman J L et al. Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer.  J Clin Oncol. 2007;  25 5359-5365
• 24 Ebert T, Altwein J E, Shkolnikov. Hormone therapy for prostate cancer – Is cure possible after all?. The Prostate Cancer Symposium, Proceedings 2007; (Abstract 196): 169
• 25 Maillefert J F, Sibilia J, Michel F et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma.  J Urol. 1999;  161 1219-1222
• 26 Shahinian V B, Kuo Y F, Freeman J L et al. Risk of fracture after androgen deprivation for prostate cancer.  N Engl J Med. 2005;  352 154-164
• 27 Culos-Reed S N, Robinson J L, Lau H et al. Benefits of a physical activity intervention for men with prostate cancer.  J Sport Exerc Psychol. 2007;  29 118-127
• 28 Cassileth B R, Soloway M S, Vogelzang N J et al. Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group.  Qual Life Res. 1992;  1 323-329
• 29 Mottet N, Prayer-Galetti T, Hammerer P et al. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer.  BJU Int. 2006;  98 20-27
• 30 Herr H W. Quality of life in prostate cancer patients.  CA Cancer J Clin. 1997;  47 207-217
• 31 Kato T, Komiya A, Suzuki H et al. Effect of androgen deprivation therapy on quality of life in Japanese men with prostate cancer.  Int J Urol. 2007;  14 416-421
• 32 Wilt T, Nair B, MacDonald R et al. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. The Cochrane database of Systematic Reviews 2001
• 33 Studer U E, Whelan P, Albrecht W et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891.  J Clin Oncol. 2006;  24 1868-1876
• 34 Akaza H. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective – the effect of primary androgen deprivation therapy on stage C prostate cancer.  BJU Int. 2007;  99 Suppl 1 10-12
• 35 Tyrrell C J, Altwein J E, Klippel F et al. Comparison of an LH-RH analogue (Goeserelin acetate, “Zoladex”) with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized-trial. International Prostate Cancer Study Group.  Eur Urol. 2000;  37 205-211
• 36 Kumar S, Shelley M, Harrison C et al. Neoadjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. The Cochrane Database for Systematic Reviews 2006
• 37 Messing E M, Manola J, Sarosdy M et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.  N Engl J Med. 1999;  341 1781-1788
• 38 Wirth M P, Weissbach L, Marx F J et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer.  Eur Urol. 2004;  45 267-270
• 39 McLeod M G. The effective management of biochemical recurrence in patients with prostate cancer.  Rev Urol. 2005;  7 29-36
• 40 Messing E M, Manola J, Yao J et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.  Lancet Oncol. 2006;  7 472-479
• 41 D’Amico A V, Manola J, Loffredo M et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.  JAMA. 2004;  292 821-827
• 42 D’Amico A V, Chen M H, Renshaw A A et al. Androgen suppression and radiation vs. radiation alone for prostate cancer: a randomized trial.  JAMA. 2008;  299 289-295
• 43 Berthelet E, Pickles T, Truong P T et al. What is the optimal duration of androgen deprivation therapy in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng / ml?.  Can J Urol. 2007;  14 3621-3627
• 44 Bruchovsky N, Klotz L, Crook J et al. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.  Cancer. 2007;  109 858-867
• 45 Miller K, Steiner U, Lingnau A et al. Randomised prospective study of intermeittent versus continuous androgen suppression in advanced prostate cancer. 2007
• 46 D’Amico A V. Gobal update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective-identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.  BJU Int. 2007;  99 13-16
• 47 Moul J W, Wu H, Sun L et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.  J Urol. 2004;  171 1141-1147
• 48 Tunn U, Canepa G, Hillger H et al. Intermittent androgen deprivation in patients with PSA-relapse after radical prostatectomy-final results of a European randomized prospective phase III-clinical trial AUO study AP06 / 95, EC 507. 2007
• 49 D’Amico A V, McLeod D G, Carroll P R et al. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality.  Cancer. 2007;  109 1290-1295
• 50 Berruti A, Mosca A, Porpiglia F et al. Chromogranin A expression in patients with hormone naive prostate cancer predicts the development of hormone refractory disease.  J Urol. 2007;  178 838-843
• 51 Shahinian V B, Kuo Y F, Freeman J L et al. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.  Cancer. 2005;  103 1615-1624
• 52 Murthy V, Norman A R, Shahidi M et al. Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer.  BJU Int. 2006;  97 476-479
• 53 Shahidi M, Norman A R, Gadd J et al. Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer.  Clin Oncol (R Coll Radiol). 2001;  13 291-295
• 54 Gulley J L, Figg W D, Steinberg S M et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.  J Urol. 2005;  173 1567-1571
• 55 Oefelein M G. Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment.  Urology. 1999;  54 694-699
• 56 Crook J M, Szumacher E, Malone S et al. Intermittent androgen suppression in the management of prostate cancer.  Urology. 1999;  53 530-534
• 57 Nejat R J, Rashid H H, Bagiella E et al. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy.  J Urol. 2000;  164 1891-1894
• 58 Goldenberg S L, Bruchovsky N, Gleave M E et al. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.  Urology. 1995;  45 839-844
• 59 Kaku H, Saika T, Tsushima T et al. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.  Prostate. 2006;  66 439-444
• 60 Hall M C, Fritzsch R J, Sagalowsky A I et al. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.  Urology. 1999;  53 898-902
• 61 Kobayashi T, Nishizawa K, Mitsumori K. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.  Scand J Urol Nephrol. 2006;  40 198-203